Form 4: Elicio CSO Exercises Stock Options Under 10b5-1 Plan

Elicio Therapeutics' Chief Scientific Officer, Peter DeMuth, exercised stock options to acquire 362 shares of common stock at $4.41 per share.

Summary

• Peter DeMuth, Chief Scientific Officer of Elicio Therapeutics, Inc. (ELTX), exercised stock options.
• The transaction occurred on December 9, 2025, as part of a pre-arranged Rule 10b5-1(c) plan.
• DeMuth acquired 362 shares of Elicio Therapeutics common stock.
• The exercise price for these shares was $4.41 per share.
• Following this transaction, DeMuth beneficially owns 743 shares of common stock directly.
• The stock options vested 25% on December 10, 2016, with the remaining shares vesting at a rate of 2.0833% at the end of each month thereafter.

Sentiment

Score: 6

Explanation: The exercise of stock options by a Chief Scientific Officer, especially under a 10b5-1 plan, is a routine event. However, the increase in direct beneficial ownership by an insider can be viewed as a mildly positive signal of confidence in the company's future.

Positives

• An insider (Chief Scientific Officer) is increasing direct ownership in the company, which can signal confidence in future performance.

Negatives

• No explicit negatives identified in this routine insider transaction filing.

Risks

• No specific risks are mentioned in this Form 4 filing.

Future Outlook

The filing indicates a transaction made pursuant to a Rule 10b5-1(c) plan, suggesting a pre-arranged future transaction, but provides no explicit forward-looking statements or guidance on company performance.

Management Comments

• The stock option vested and became exercisable as to (i) 25% of the options on the first anniversary of the grant date or December 10, 2016, and (ii) with the remaining shares vesting at a rate of 2.0833% at the end of each month thereafter.

Industry Context

This is a routine insider transaction and does not provide specific details to analyze broader industry trends or competitive landscape. However, insider buying, even small, can sometimes be seen as a positive signal within the biotech industry, indicating management's belief in the company's pipeline or future prospects.

Comparison to Industry Standards

• Not applicable. This Form 4 filing details a specific insider transaction and does not contain information suitable for comparison to global benchmarks, comparable companies, projects, or results.

Related Party Transactions

• The transaction involves an insider (Chief Scientific Officer Peter DeMuth) acquiring shares from the company, which is a common form of related party transaction in the context of executive compensation.

Stakeholder Impact

• Shareholders: The increase in insider ownership could be perceived as a positive signal of management confidence.
• Employees: No direct impact on employees is indicated.
• Customers/Suppliers/Creditors: No direct impact on these stakeholders is indicated.

Next Steps

• No specific future actions or milestones are mentioned in this Form 4 filing beyond the transaction itself.

Key Dates

Recommendation

This Form 4 filing details a routine insider transaction (exercise of stock options under a 10b5-1 plan) by the Chief Scientific Officer. While an increase in insider ownership can be a positive signal, the relatively small number of shares (362) and the pre-planned nature of the transaction do not provide sufficient new information to warrant a change in investment recommendation. Investors should consider broader company fundamentals and market conditions.

Keywords

Elicio Therapeutics, ELTX, Peter DeMuth, Stock Option Exercise, Insider Transaction, Form 4, Beneficial Ownership, Chief Scientific Officer, 10b5-1 Plan